{"id":229,"date":"2018-02-02T00:00:00","date_gmt":"2018-02-02T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/\/index.php\/2018\/02\/02\/ttfields-tied-to-improved-survival-in-glioblastoma-patients\/"},"modified":"2018-02-02T00:00:00","modified_gmt":"2018-02-02T00:00:00","slug":"ttfields-tied-to-improved-survival-in-glioblastoma-patients","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2018\/02\/02\/ttfields-tied-to-improved-survival-in-glioblastoma-patients\/","title":{"rendered":"TTFields Tied to Improved Survival in Glioblastoma Patients"},"content":{"rendered":"<h3>No negative influence on health-related quality of life apart from more itchy skin, which was expected<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>FRIDAY, Feb. 2, 2018 (HealthDay News) &#8212; For patients with glioblastoma, the addition of tumor-treating fields (TTFields) to standard treatment with temozolomide is associated with improved survival without negative effects on health-related quality of life (HRQoL) other than itchy skin, according to a study published online Feb. 1 in <i>JAMA Oncology<\/i>.<\/p>\n<p>Martin J.B. Taphoorn, M.D., from the Haaglanden Medical Center in the Netherlands, and colleagues examined the correlation of TTFields therapy with progression-free survival and HRQoL among patients with glioblastoma. A total of 695 patients with glioblastoma were randomized after radiochemotherapy to TTFields and temozolomide or temozolomide alone in a 2-to-1 ratio. Temozolomide was given for five days each 28-day cycle. TTFields were delivered continuously via transducer arrays placed on the shaved scalp of patients.<\/p>\n<p>The researchers found that there was no significant between-group difference in HRQoL except for more itchy skin with TTFields. Significantly longer deterioration-free survival was seen with TTFields for global health, physical and emotional functioning, pain, and leg weakness, likely related to improved progression-free survival. Reflecting the influence of treatment, time to deterioration did not differ significantly except for itchy skin (TTFields worse: 8.2 versus 14.4 months) and pain (TTFields improved: 13.4 versus 12.1 months). TTFields did not affect role, social, or physical functioning.<\/p>\n<p>&#8220;The addition of TTFields to standard treatment with temozolomide for patients with glioblastoma results in improved survival without a negative influence on HRQoL except for more itchy skin, an expected consequence from the transducer arrays,&#8221; the authors write.<\/p>\n<p>Several authors disclosed financial ties to pharmaceutical and medical technology companies, including Novocure, which funded the study.<\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2670704\" target=\"_new\">Abstract\/Full Text<\/a><\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2670701\" target=\"_new\">Editorial (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2018 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\">HealthDay<\/a>. All rights reserved.<\/i>   <\/p>\n","protected":false},"excerpt":{"rendered":"<p>No negative influence on health-related quality of life apart from more itchy skin, which was expected<\/p>\n","protected":false},"author":6,"featured_media":230,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-229","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=229"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/229\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/230"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}